List All Melanoma Trials


pIL-12 Electroporation for Malignant Melanoma
A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma
Status Conditions Phase Study ID
Recruiting Melanoma Phase II NCT01502293

Determine the 24-week distant response rate (complete and partial) of patients with advanced cutaneous melanoma treated with IL-12 plasmid electroporation.

Shailender Bhatia, M.D.
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  1. Pathologically documented melanoma, AJCC stage IIIB, IIIC or IV M1a with cutaneous melanoma lesions accessible to electroporation. Patients with Stage IIIB or IIIC disease may have cutaneous in-transit disease or cutaneous satellitosis and patients with Stage IV M1a disease may have either of these with distant cutaneous metastatic sites.
  2. Age ≥ 18 years old
  3. ECOG performance status 0-2
  4. Patients may have had prior chemotherapy or immunotherapy (with vaccines or Interferon or IL-2) with progression or persistent disease. All chemotherapy or immunotherapy must be stopped 4 weeks prior to electroporation. Patients may have had radiation therapy, but must have progressive disease after radiation therapy if the lesions to be electroporated are within the radiation field. In addition, it must be at least 2 weeks since administration of radiation therapy and all signs of toxicity must have abated.
  5. Must have a minimum of two eligible tumors and may have up to four eligible tumors treated with electroporation.
  6. Creatinine < 2 x upper limit of normal, and serum bilirubin within institutional normal limits obtained within 4 weeks prior to registration.
  7. Absolute neutrophil count (ANC) > 1000/mm and platelet count > 100,000 /mm within 4 weeks prior to registration.
  8. Able to give informed consent and able to follow guidelines given in the study
Exclusions (conditions that would prevent participation in this study)
  1. Prior therapy with IL-12 or prior gene therapy
  2. Concurrent immunotherapy, chemotherapy, or radiation therapy
  3. Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
  4. Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
  5. Women of childbearing age must have a negative pregnancy test and be willing to use a highly effective method of contraception. Men who are sexually active must also be willing to use an accepted and effective method of contraception.
  6. Patients with electronic pacemakers or defibrillators are excluded from this study as the effect of electroporation on these devices is unknown.
  7. Life expectancy of less than 6 months
Last Updated
July 23, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.